Invirsa, a Columbus, Ohio-based pharmaceutical company developing a new line of attack against common infectious diseases, closed $520k in seed funding.
The round was led by Rev1 Ventures.
The company intends to use the funds to bring INV-102 into clinical development.
Founded by experienced drug developer Robert Shalwitz MD, and VP Isaiah Shalwitz, MS, a biostatistician and pharmaceutical development veteran, most recently a co-founder of Akebia Therapeutics (NASDAQ: AKBA) and Aerpio Pharmaceuticals (OTCMKTS:ARPO), Invirsa is a pharmaceutical company that focuses on enhancing the body’s natural defenses to both protect and fight off challenging infectious diseases.
Its lead drug candidate, INV-102, derived from a naturally occurring small molecule, works by strengthening the innate immune response and stimulating the repair of damaged DNA. The company is initially developing INV-102 as a primary treatment for acute keratoconjunctivitis, also known as “pinkeye,” as well as upper respiratory tract infections.